Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)
Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –
Neurocrine Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Neurocrine Biosciences's revenue for the twelve months ending Jun 30, 2026 was $3.37B, up 34.4% year over year. For fiscal 2025 it was $2.86B, up 21.4% from the year before. Over ten years it grew 64.5% a year on average. The highest annual figure on record is $2.86B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86B | +21.4% |
| FY2024 | Dec 31, 2024 | $2.36B | +24.8% |
| FY2023 | Dec 31, 2023 | $1.89B | +26.8% |
| FY2022 | Dec 31, 2022 | $1.49B | +31.3% |
| FY2021 | Dec 31, 2021 | $1.13B | +8.4% |
| FY2020 | Dec 31, 2020 | $1.05B | +32.7% |
| FY2019 | Dec 31, 2019 | $788.10M | +74.7% |
| FY2018 | Dec 31, 2018 | $451.20M | +179.2% |
| FY2017 | Dec 31, 2017 | $161.63M | +977.5% |
| FY2016 | Dec 31, 2016 | $15.00M | -24.1% |
| FY2015 | Dec 31, 2015 | $19.77M | – |
| FY2014 | Dec 31, 2014 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $2.92M | -94.5% |
| FY2012 | Dec 31, 2012 | $53.14M | -31.4% |
| FY2011 | Dec 31, 2011 | $77.41M | +131.1% |
| FY2010 | Dec 31, 2010 | $33.50M | +1034.5% |
| FY2009 | Dec 31, 2009 | $2.95M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $959.00M | +39.5% |
| Q1 FY2026 | Mar 31, 2026 | $814.50M | +42.2% |
| Q4 FY2025 | Dec 31, 2025 | $805.50M | +28.3% |
| Q3 FY2025 | Sep 30, 2025 | $794.90M | +27.8% |
| Q2 FY2025 | Jun 30, 2025 | $687.50M | +16.5% |
| Q1 FY2025 | Mar 31, 2025 | $572.60M | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | $627.70M | +21.8% |
| Q3 FY2024 | Sep 30, 2024 | $622.10M | +24.7% |
| Q2 FY2024 | Jun 30, 2024 | $590.20M | +30.4% |
| Q1 FY2024 | Mar 31, 2024 | $515.30M | +22.6% |
| Q4 FY2023 | Dec 31, 2023 | $515.20M | +25.0% |
| Q3 FY2023 | Sep 30, 2023 | $498.80M | +28.6% |
| Q2 FY2023 | Jun 30, 2023 | $452.70M | +19.7% |
| Q1 FY2023 | Mar 31, 2023 | $420.40M | +35.4% |
| Q4 FY2022 | Dec 31, 2022 | $412.00M | +32.1% |
| Q3 FY2022 | Sep 30, 2022 | $387.90M | +31.0% |
| Q2 FY2022 | Jun 30, 2022 | $378.20M | +30.9% |
| Q1 FY2022 | Mar 31, 2022 | $310.60M | +31.3% |
| Q4 FY2021 | Dec 31, 2021 | $312.00M | +25.9% |
| Q3 FY2021 | Sep 30, 2021 | $296.00M | +14.5% |
| Q2 FY2021 | Jun 30, 2021 | $288.90M | -4.5% |
| Q1 FY2021 | Mar 31, 2021 | $236.60M | -0.2% |
| Q4 FY2020 | Dec 31, 2020 | $247.90M | +1.6% |
| Q3 FY2020 | Sep 30, 2020 | $258.50M | +16.4% |
| Q2 FY2020 | Jun 30, 2020 | $302.40M | +64.8% |
| Q1 FY2020 | Mar 31, 2020 | $237.10M | +71.3% |
| Q4 FY2019 | Dec 31, 2019 | $244.10M | +85.6% |
| Q3 FY2019 | Sep 30, 2019 | $222.10M | +46.4% |
| Q2 FY2019 | Jun 30, 2019 | $183.50M | +89.4% |
| Q1 FY2019 | Mar 31, 2019 | $138.40M | +94.7% |
| Q4 FY2018 | Dec 31, 2018 | $131.49M | +39.1% |
| Q3 FY2018 | Sep 30, 2018 | $151.76M | +149.7% |
| Q2 FY2018 | Jun 30, 2018 | $96.91M | +1429.7% |
| Q1 FY2018 | Mar 31, 2018 | $71.09M | – |
| Q4 FY2017 | Dec 31, 2017 | $94.52M | – |
| Q3 FY2017 | Sep 30, 2017 | $60.77M | – |
| Q2 FY2017 | Jun 30, 2017 | $6.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?